Next Article in Journal / Special Issue
Lipid-Lowering Effects of Ethyl 2-Phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in Rodents
Previous Article in Journal / Special Issue
Kinetics of the Epoxidation of Geraniol and Model Systems by Dimethyldioxirane
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Unexpected Syntheses of seco-Cyclopropyltetrahydroquinolines >From a Radical 5-Exo-Trig Cyclization Reaction: Analogs of CC-1065 and the Duocarmycins

Department of Chemistry, Furman University, Greenville, SC 29613, USA
*
Author to whom correspondence should be addressed.
Molecules 2004, 9(3), 125-133; https://doi.org/10.3390/90300125
Submission received: 13 January 2004 / Revised: 28 January 2004 / Accepted: 29 January 2004 / Published: 28 February 2004
(This article belongs to the Special Issue Biologically Relevant Heterocyclic Compounds)

Abstract

:
Analogs of the seco-cyclopyrroloindoline (seco-CPI), the DNA alkylation pharmacophore of CC-1065 and the duocarmycins, can be prepared through a 5-exo-trig radical cyclization of a free radical and a 3-chloro-2-allylic moiety. This manuscript reports an unexpected discovery that, depending on the structure and stability of the free radical, the cyclization process leads to the production of an appreciable amount of seco-cyclopropyltetrahydroquinolines 7a-d along with the seco-cyclopropoyltetra-hydroindoline products (6a-e). For instance, free radical reaction of the bromoallylic chloride 5a produced an equal amount of 6-benzyloxy-N-t-butoxycarbonyl-3-(chloromethyl)furano[e]indoline (6a), and 7-benzyloxy-N-t-butoxycarbonyl-3-chloro-1,2,3,4-tetrahydrofurano[f]quinoline (7a). Three other examples that produced mixtures of indoline and quinoline products are provided. In only one of the examples reported in this manuscript, the 6-benzyloxy-N-t-butoxycarbonyl-3-(chloromethyl)benzo[e]indoline, was a seco-CBI precursor 6e formed exclusively, consistent with literature precedents.

Introduction

CC-1065 (1) and the duocarmycins [such as duocarmycin SA (2), duocarmycin C1 (3) and duocarmycin C2 (4)], whose structures are given in Figure 1, are members of an extremely potent group of anticancer agents that contain an interesting cyclopropylpyrroloindolone (CPI) DNA alkylating functionality. These compounds also consist of a non-covalently active portion, the phosphoidiesterase inhibitor (PDE) moiety in CC-1065 and the 5,6,7-trimethoxyindole-2-carbonyl group in the duocarmycins [1,2]. Upon binding within the minor groove of AT-rich sequences of DNA, notably at 5-TTA-3’, the reactivity of the cyclopropane is enhanced by a million fold for reaction with the adenine-N3 atoms to form a covalent bond [3]. Two mechanisms have been proposed for the DNA-binding enhancement in reactivity of the cyclopropane with nucleophiles: the alkylation [4] and non-covalent driven model [5]. Covalent interaction of CC-1065 and the duocarmycins with DNA has been found to kill cancer cells by inducing the cells to undergo apoptosis [6].
Figure 1. Structures of CC-1065 (1) and the duocarmycins, such as duocarmycin SA (2), duocarmycin C1 (3) and duocarmycin C2 (4).
Figure 1. Structures of CC-1065 (1) and the duocarmycins, such as duocarmycin SA (2), duocarmycin C1 (3) and duocarmycin C2 (4).
Molecules 09 00125 g001
Due to their potent anticancer properties, CC-1065 and the duocarmycins have enjoyed significant levels of attention. This attention has led to the development of several analogs that have superior activity over CC-1065 and the duocarmycins, and several analogs have been selected for clinical evaluation. Examples of such compounds include adozelesin [5], carzelesin [6], KW5189 [7], and bizelesin [8]. However, due to their severe toxicity to the bone marrow, currently only bizelesin remains in clinical evaluation. In an attempt to design novel analogs of the duocarmycins and CC-1065 with reduced toxicity to bone marrow cells, a wide range of analogs of the cyclopropyl-pyrrolo[e]indolone (CPI) subunit were synthesized and tested. Examples of such analogs, cyclopropylbenzo[e]indolone (CBI) [9], cyclopropylpyrazolo[e]indolone (CPzI) [10], cyclopropyl-furano[e]indolone (CFI) [11], and cyclopropylindolone (CI) [12], are given in Figure 2. We have contributed to this list of analogs by the design and synthesis of an iso-cyclopropylfurano[e]indolone (iso-CFI) pharmacophore, a highly cytotoxic pharmacophore that is significantly less toxic to murine bone marrow cells than the corresponding CBI analogs [13]. As depicted in Figure 3, synthesis of the iso-CFI intermediate relied on the free radical 5-exo-trig cyclization in refluxing toluene of the bromoallylic chloride 5a in the presence of 2,2'-azobisisobutyronitrile (AIBN) and tributyltin hydride. To our surprise, radical cyclization of compound 5a gave not only the iso-CFI precursor, indoline 6a, but it also afforded an equal amount of a CFQ precursor, quinoline 7a. In order to further explore whether the unexpected ring closure process that led to the production of quinoline products is more common, or whether the formation of compound 7a represented an exceptional behavior, the 5-exo-trig radical cyclizations of five different bromoallylic chlorides 5a-e were studied.
Figure 2. Strucutres of the cyclopropylpyrrolo[e]indolone (CPI), cyclopropylbenzo-[e]indolone (CBI), cyclopropylpyrazolo[e]indolone (CPzI), cyclopropylfurano[e]-indolone (CFI), and cyclopropylindolone (CI) analogs.
Figure 2. Strucutres of the cyclopropylpyrrolo[e]indolone (CPI), cyclopropylbenzo-[e]indolone (CBI), cyclopropylpyrazolo[e]indolone (CPzI), cyclopropylfurano[e]-indolone (CFI), and cyclopropylindolone (CI) analogs.
Molecules 09 00125 g002

Results and Discussion

Syntheses of the benzofuran bromoallylic chlorides 5a and 5b were accomplished according to a procedure recently published from our laboratory [13]. Using a similar approach, and an appropriate starting material, such as thiophene-2-carboxaldehyde and 3-bromobenzaldehyde, the corresponding bromoallylic chlorides 5c and 5d were prepared. The naphthalene bromoallylic chloride 5e was prepared according to a literature process [14]. With the five compounds 5a-e at hand, their free radical promoted ring closure reactions were carried out as depicted in Figure 3. Each compound 5a-e was treated with 0.33 mole-equivalents of AIBN and 2.5 mole-equivalents of tributyltin hydride. The mixture was dissolved in freshly distilled (over sodium) toluene or benzene and the solution was thoroughly deoxygenated by degassing the same under vacuum and opening the flask to nitrogen (three times). The resulting clear solutions were heated to reflux under a nitrogen atmosphere for 5 hours, at which time the reactions were completed as monitored by TLC analyses. Because of their different structures, the indoline compounds (6) were separated readily from the more polar quinoline compounds (7) by chromatography. In all cases the unpurified products, as well as the silica gel column purified compounds (6 and 7) were analyzed by 500 MHz 1H-NMR. As indicated in the Experimental section, the indoline and quinoline compounds gave characteristic spectra, each bearing peaks in the 3.5-4.5 ppm region. As depicted in Figure 4A, the spectrum of indoline 6a gave four sets of peaks in this region, with two distinct triplet-like patterns at 3.6 and 4.2 ppm. Quinoline 7a, as shown in Figure 4B, gave a simpler spectrum in this region, with one distinct triplet in the 4.2 ppm position and a multiplet at 3.6 ppm. As illustrated in Figure 4C, the spectrum for the unpurified material indicated a mixture of 6a and 7a, at a ratio of 1:1.2. The products for reactions of compounds 5b-e are summarized in Table 1.
Table 1. Summary of the percent yields and product ratios resulting from the radical cyclizations of bromoallylic chlorides 5a-e.
Table 1. Summary of the percent yields and product ratios resulting from the radical cyclizations of bromoallylic chlorides 5a-e.
ReactantIndoline (6)Quinoline (7)Ratio of 6:7
5a40%48%1:1.2
5b37321.2:1
5c35321.1:1
5d29191.5:1
5e86none isolatednot calculated
Formation of substantial amounts of the seco-cyclopropyltetrahydroquinoline products 7a-d, in addition to their 5-exo-trig (seco-iso-CFI) counterparts 6a-d, is noteworthy. This type of radical cyclization process on a diverse range of structures, including compound 5e, has been widely reported [14]. In all of the reported cases, the indoline or 5-exo-trig products were obtained exclusively [11b,14], including the formation of a seco-CBI precursor (indoline 6e) from bromoallylic chloride 5e. We propose that formation of the quinolines 7a-d is due to the generation of a stabilized radical intermediate, formed via a 5-exo-trig ring closure reaction. Instead of immediately reacting with tributyltin hydride, the radical intermediate undergoes a ring expansion reaction to produce a more stable intermediate, which has a six-membered ring (quinoline) structure. The free radical is further stabilized by conjugation of the radical at the benzylic position. Subsequent reaction of the seco-CFQ radical with tributyltin hydride afforded products 7a-d.
Figure 3. Free radical promoted cyclization of bromo-allylic chlorides 5a-e
Figure 3. Free radical promoted cyclization of bromo-allylic chlorides 5a-e
Molecules 09 00125 g003
With both quinoline (7) and indoline (6) products available, they were conjugated to a 5,6,7-trimethoxyindole-2-carboxylic acid moiety, thereby forming analogs of the duocarmycins. Conjugates of compounds 6a,b and 7a,b to the trimethoxyindole moiety were found to have significant, yet similar, cytotoxicity against the growth of cancer cells grown in culture. The IC50 values for these compounds derived from a three-day drug exposure against murine B16 melanoma are 0.04 – 0.09 μM [13].
Figure 4. Expanded 500 MHz 1H-NMR spectra of indoline 6a (A), quinoline 7a (B) and an unpurified sample of 6a and 7a (C).
Figure 4. Expanded 500 MHz 1H-NMR spectra of indoline 6a (A), quinoline 7a (B) and an unpurified sample of 6a and 7a (C).
Molecules 09 00125 g004

Acknowledgements

The authors acknowledge support from the NSF-REU, NIH (RR16461-10) from the BRIN Program, and Furman University.

Experimental

General

Instruments, etc

General Procedure for the Free Radical 5-Exo-Trig Cyclization

6-Benzyloxy-N-t-butoxycarbonyl-3-(chloromethyl)furano[e]indoline (6a) and 7-benzyloxy-N-t-butoxy-carbonyl-3-chloro-1,2,3,4-tetrahydronfurano[f]quinoline (7a). To a mixture of cis and trans bromo allylic-chloride 5a (1.37 g, 2.59 mmol) was added 2,2'-azobisisobutyronitrile (AIBN) (250 mg, 1.52 mmol). The reagents were then dissolved in freshly distilled toluene (140 mL), and nBu3SnH (1.87 mL, 6.95 mmol) was added. The solution was degassed with nitrogen and heated in an oil bath (90°C) for 2 hours. The toluene was removed in vacuo to produce a light yellow oil which was dissolved in CH2Cl2 and loaded on a hexane/silica gel column. The products were eluted with 1% EtOAc/hexane with the composition of EtOAc gradually increased to 5%. Fractions containing the products were concentrated in vacuo. The expected indoline product 6a was obtained as a colorless clear oil (430 mg, 1.03 mmol, 40%); TLC (10% EtOAc/hexane) Rf = 0.52; IR (KBr, cm-1) 3070, 3024, 2971, 2927, 1701, 1652, 1634, 1617, 1559, 1541, 1493, 1457, 1417, 1368, 1342, 1257, 1155, 1080, 1049, 1023, 978, 929, 903, 858, 823, 788, 739, 712; 1H-NMR (CDCl3) 7.57 (s br, 1H), 7.41 (d br, 8.0, 2H), 7.35 (d, 2.5, 1H), 7.33 (t, 8.0, 2H), 7.28 (t, 8.0, 1H), 6.77 (d, 2.5, 1H), 5.13 (s, 2H), 4.15 (dd, 9.5, 10.0, 1H), 4.02 (dd, 4.0, 11.0, 1H), 3.98 (m, 1H), 3.92 (dt, 4.0, 10.0, 1H), 3.54 (t, 10.5, 1H), 1.51 (s, 9H); EI-MS (m/z rel. intensity) 413 (M+, 14); Accurate mass for C23H24NO435Cl: calcd. 413.1394, obsd. 413.1381.
In addition to the inoline product 6a, an unexpected quinoline substance 7a was isolated as a colorless clear oil (513 mg, 1.24 mmol, 48%); TLC (10% EtOAc/hexane) Rf = 0.51; IR (KBr, cm-1) 3122, 3069, 2971, 2927, 1701, 1639, 1612, 1493, 1457, 1417, 1368, 1342, 1258, 1222, 1160, 1138, 1084, 1071, 1049, 1023, 903, 858, 832, 756, 734, 694; 1H-NMR (CDCl3) 7.57 (s br, 1H), 7.41 (d br, 7.5, 2H), 7.36 (d, 2.0, 1H), 7.33 (t, 7.5, 2H), 7.27 (t, 7.5, 1H), 6.76 (d, 2.0, 1H), 5.13 (s, 2H), 4.17 (t, 9.5, 2H), 3.5-3.65 (m, 3H), 1.49 (s, 9H); EI-MS (m/z, rel. intensity) 413 (M+, 4), 379 (M++ H-Cl, 20); Accurate mass for C23H24NO435Cl: calcd. 413.1394, obsd. 413.1384.
Note: The radical cyclization of pure cis or trans isomer of compound 5a gave similar mixtures of products 6a and 7a.
6-Benzyloxy-N-t-butoxycarbonyl-3-(chloromethyl)-5-methylfurano[e]indoline (6b), and 7-benzyloxy-N-t-butoxycarbonyl-3-chloro-1,2,3,4-tetrahydro-5-methylfurano[f]quinoline (7b). The products were purified by silica gel column chromatography using 10% EtOAc/petroleum ether as eluent to give compounds 6b and 7b in 37% and 32% yield, respectively. Indoline 6b was isolated as an off-white solid. Mp. 170-172°C; TLC (10% EtOAc/petroleum ether) Rf = 0.44; IR (KBr, cm-1) 3045, 2965, 2927, 2856, 1701, 1638, 1621, 1493, 1457, 1417, 1368, 1342, 1258, 1213, 1164, 1146, 1058, 1027, 934, 898, 752; 1H-NMR (CDCl3) 7.58 (s br, 1H), 7.43 (d br, 2H), 7.38 (t, 8.0, 2H), 7.24 (t, 8.0, 1H), 6.45 (s, 1H), 5.23 (s, 2H), 4.20 (dd, 9.5, 10.0, 1H), 4.10 (dd, 4.0, 10.0, 1H), 4.06 (m, 1H), 3.97 (dt, 4.0, 10.0, 1H), 3.59 (t, 10.0, 1H), 2.41 (s, 3H), 1.61 (s, 9H); EIMS m/z (rel. intensity) 427 (M+, 15), 371 (67), 91 (100).
Quinoline product 7b: Yellowish oil; TLC (10% EtOAc/petroleum ether) Rf = 0.40; IR (KBr, cm-1) 3040, 2964, 2927, 1701, 1639, 1497, 1458, 1417, 1458, 1417, 1368, 1342, 1320, 1213, 1164, 1142, 1049, 974, 934, 898, 832, 761, 734, 694; 1H-NMR (CDCl3) 7.59 (s br, 1H), 7.47 (s br, 2H), 7.39 (t, 7.5, sH), 7.34 (d, 7.5, 1H), 6.44 (s, 1H), 5.17 (s, 2H), 4.22 (t, 9.5, 2H), 3.65 (m, 3H), 2.41 (s, 3H), 1.60 (s, 9H); EIMS m/z (rel. intensity) 427 (M+, 2), 393 (30), 337 (100).
6-Benzyloxy-N-t-butoxycarbonyl-3-(chloromethyl)thiopheno[e]indoline (6c) and 7-benzyloxy-N-t-butoxycarbonyl-3-chloro-1,2,3,4-tetrahydrothiopheno[f]quinoline (7c). The products were putified by column chromatography using 5% ethyl acetate/petroleum ether as eluent. Both products were viscous and colorless oils. Indoline 6c: TLC (5% EtOAc/petroleum ether) Rf = 0.62; IR (KBr, cm-1) 3010, 2963, 1705, 1697, 1438, 1461, 1394, 1368, 1337, 1293, 1257, 1223, 1164, 1142, 1116; 1H-NMR (CDCl3) 7.45 (m, 6H), 7.32 (t, 7.5, 1H), 7.17 (d, 5.0, 1H), 5.21 (s, 2H), 4.21 (m, 2H), 4.05 (dd, 2.0, 9.9, 1H), 3.87 (m, 1H), 3.62 (t, 10.5, 1H), 1.59 (s, 9H); EIMS m/z (rel. intensity) 430 [M+, 10].
Quinoline 7c: TLC (5% EtOAc/petroleum ether) Rf = 0.55; IR (KBr, cm-1) 3007, 1953, 1700, 1607, 1483, 1461, 1394, 1368, 1332, 1292, 1142 and 1120; 1H-NMR (CDCl3) 7.54 (s, 7.0, 2H), 7.53 (d, 5.0, 1H), 7.44 (t, 7.0, 1H), 7.36 (t, 7.0, 1H), 7.16 (d, 5.0, 1H), 5.23 (s, 2H), 4.28 (t, 6.0, 2H), 3.68 (m, 1H), 3.61 (m, 2H), 1.59 (s, 9H); EIMS m/z (rel. intensity) 430 [M+, 6].
Butyl 5-[6-benzyloxy-N-t-butoxycarbonyl-3-(chloromethyl)benzo[e]indoline]carboxylate (6d) and butyl 5-[7-benzyloxy-N-t-butoxycarbonyl-3-chloro-1,2,3,4-tetrahydrobenzo[f]quinoline]carboxylate (7d). Silica gel column chromatography purification of the crude product using 5% EtOAc/hexane as eluent afforded compounds 6d and 7d in 29% and 19%, respectively. Compound 6d was isolated as a white solid. Mp 146-149°C; TLC (10% EtOAc/hexane) Rf = 0.55; IR (KBr, cm-1) 2961, 1701, 1409, 1363, 1329, and 1141; 1H-NMR (CDCl3, 500 MHz) 8.38 (d, 2.0, 1H), 8.33 (d, 8.0, 1H), 7.90 (dd, 2.0, 8.0, 1H), 7.54 (d, 8.0, 1H), 7.42 (m, 5H), 5.30 (s, 2H), 4.40 (t, 6.0, 2H), 4.30 (m, 1H), 4.18 (m, 1H), 4.08 (m, 1H), 3.93 (dd, 2.5, 11.1, 1H), 3.50 (t, 11.0, 1H), 1.81 (quintet, 6.0, 2H), 1.61 (s, 9H), 1.53 (quintet, 6.0, 2H), 1.02 (t, 6.0, 3H); EIMS m/z (rel. intensity) 523 [M+, 10]; Accurate mass calcd. for C30H34NO535C l 525.2126, obsd. 525.2137.
Quinoline 7d: Colorless oily residue; TLC (10% EtOAc-Hexane) Rf = 0.51; IR (KBr, cm-1) 2991, 1704, 14062, 1368, 1328, and 1147; 1H-NMR (CDCl3, 500 MHz) 8.56 (d, 2.0, 1H), 8.36 (d, 8.0, 1H), 8.03 (s br, 1H), 7.94 (dd, 2.0, 8.0, 1H), 7.54 (d, 8.0, 7H), 7.48 (t, 8.0, 2H), 7.39 (t, 8.0, 1H), 5.30 (s, 2H), 4.40 (t, 6.0, 2H), 4.21 (t, 6.0, 2H), 3.80 (m, 3H), 1.82 (quintet, 6.0, 2H), 1.60 (s, 9H), 1.50 (quintet, 6.0, 2H), 0.98 (t, 6.0, 3H); EIMS m/z (rel. intensity) 523 [M+, 7].

References

  1. Li, L.H.; Wallace, T.L.; DeKoning, T.F.; Warpehoski, M.A.; Kelly, R.C.; Prairie, M.D.; Drueger, W.C. Invest. New Drugs 1987, 5, 329.Li, L.H.; Kelly, R.C.; Warpehoski, M.A.; McGovern, J.P.; Gebhard, I.; DeKoning, T.F. Invest. New Drugs 1991, 9, 137.(c)Warpehoski, M. Advances in DNA Sequence Specific Agents; Hurley, L.H., Ed.; JAI Press, Inc.: Greenwich, CT, 1992; Vol. 1, pp. 217–245. [Google Scholar]
  2. Boger, D.L.; Garbaccio, R.M. Acc. Chem. Res. 1999, 32, 1043.Boger, D.L.; Johnson, D.S. Angew. Chem. Int. Ed. Engl. 1996, 35, 1438.Boger, D.L.; Johnson, D.S. Proc. Natl. Acad. Sci. USA 1995, 92, 3642.Boger, D.L. Acc. Chem. Res. 1995, 28, 20.Boger, D.L. Chemtracts: Org. Chem. 1991, 4, 329.
  3. Boger, D.L.; Boyce, C.W.; Johnson, D.S. Bioorg. Med. Chem. Lett. 1997, 7, 233. [CrossRef]
  4. Boger, D.L.; Johnson, D.S.; Wassidlo, W. Bioorg. Med. Chem. Lett. 1994, 4, 631.Wang, Y.; Yuan, H.; Ye, W.; Wright, S.C.; Wang, H.; Larrick, J.W. J. Med. Chem. 2000, 43, 1541.
  5. Hightower, R.D.; Sevin, B.U.; Pevras, J.P.; Untch, M.; Angioli, R.; Averette, H. Gynecol. Oncol. 1992, 42, 186.Cote, S.; Momparler, R.L. Anti-Cancer Drugs 1993, 4, 327.Fleming, G.F.; Ratain, S.M.; O’Brien, R.L.; Schilsky, P.C.; Ramos, R.; Richards, J.M.; Vogelzang, N.J.; Kasunic, D.A.; Earhart, R.H. J. Natl. Cancer Inst. 1994, 86, 368.Foster, B.J.; Larusso, P.M.; Poplin, E.; Zalupski, M.; Valdivieso, M.; Wozniak, A.; Flaherty, L.; Kasunic, D.A.; Earhart, R.H.; Baker, L.H. Invest. New Drugs 1996, 13, 321.Burris, H.A.; Dieras, V.C.; Tunca, M.; Earhart, R.H.; Earhart, J.R.; Rodriguez, G.L.; Shaffer, D.S.; Fields, S.M.; Campbell, E.; Schaaf, L.; Kasunic, D.; Von Hoff, D.D. Anti-Cancer Drugs 1997, 8, 588.
  6. Li, L.H.; Dekoning, J.F.; Kelly, R.C.; Krueger, W.C.; McGovern, J.P.; Padbury, G.E.; Petzold, G.L.; Wallace, T.L.; Ouding, R.J.; Praire, M.D.; Gebhard, I. Cancer Res. 1992, 52, 4904.van Telligen, O.; Punt, C.J.A.; Awada, A.; Wagener, D.J.T.; Piccart, M.J.; Groot, Y.; Schaaf, L.J.; Henrar, R.E.C.; Nooijen, W.J.; Beijnen, J.H. Cancer Chemother. Pharmacol. 1998, 41, 366.
  7. Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Bioorg. Med. Chem. Lett. 1996, 6, 2147, and references therein.Alberts, S.R.; Erlichman, C.; Reid, J.M.; Sloan, J.A.; Ames, M.M.; Richardson, R.L.; Goldberg, R.M. Clin. Cancer Res. 1998, 4, 2111.
  8. Walker, D.L.; Reid, F.M.; Ames, M.M. Cancer Chemother. Pharmacol. 1994, 34, 317–322.Volpe, D.A.; Tomaszewski, J.E.; Parchment, R.E.; Garg, A.; Flora, K.P.; Murphy, M.J.; Grieshaber, C.K. Cancer. Chemother. Pharmacol. 1996, 39, 143.Pitot IV, H.C.; Erlichman, C.; Reid, J.M.; Sloan, J.A.; Ames, M.M.; Bagniewski, P.G.; Atherton-Skaaf, P.; Adjei, A.A.; Rubi, J.; Rayson, D.; Goldberg, R.M. Proc. Am. Assoc. Cancer Res. 1999, 40, 91.
  9. Boger, D.L.; McKie, J.A. J. Org. Chem. 1995, 60, 1271.Boger, D.L.; Yun, W.; Han, N. Bioorg. Med. Chem. 1995, 3, 1429.
  10. Baraldi, P.G.; Cacciari, B.; Pinedo de las Infantas, M.J.; Romagnoli, R.; Spatullo, G.; Cozzi, P.; Mongelli, N. Anti-Cancer Drug Design 1997, 12, 67.
  11. Mohamadi, F.; Spees, M.M.; Staten, G.S.; Marder, P.; Kipka, J.K.; Johnson, D.A.; Boger, D.L.; Zarrinmayeh, H. J. Med. Chem. 1994, 37, 232.Patel, V.F.; Andis, S.L.; Enkema, J.K.; Johnson, D.A.; Kennedy, J.H.; Mohamadi, F.; Schultz, R.M.; Soose, D.J.; Spees, M.M. J. Org. Chem. 1997, 62, 8868.
  12. Boger, D.L.; Munk, S.A.; Zarrinmayeh, H.; Ishizaki, T.; Haught, J.; Bina, M. Tetrahedron 1991, 47, 2661.Boger, D.L.; Ishizaki, T.; Zarrinmayeh, H.; Munk, S.A.; Kitos, P.A.; Suntorwart, O. J. Am. Chem. Soc. 1990, 112, 8961.
  13. Howard, T.T.; Lingerfelt, B.M.; Purnell, B.L.; Scott, A.E.; Price, C.A.; Townes, H.M.; McNulty, L.; Handl, H.L.; Summerville, K.; Hudson, S.J.; Bowen, P.J.; Kiakos, K.; Hartley, J.A.; Lee, M. Bioorg. Med. Chem. 2002, 10, 2941. [CrossRef]
  14. Boger, D.L.; Boyce, C.W.; Garbaccio, R.M.; Searcey, M. Tetrahedron Lett. 1998, 39, 2227.
  • Sample Availability: Available from authors

Share and Cite

MDPI and ACS Style

Pati, H.; Forrest, L.; Townes, H.; Lingerfelt, B.; McNulty, L.; Lee, M. Unexpected Syntheses of seco-Cyclopropyltetrahydroquinolines >From a Radical 5-Exo-Trig Cyclization Reaction: Analogs of CC-1065 and the Duocarmycins. Molecules 2004, 9, 125-133. https://doi.org/10.3390/90300125

AMA Style

Pati H, Forrest L, Townes H, Lingerfelt B, McNulty L, Lee M. Unexpected Syntheses of seco-Cyclopropyltetrahydroquinolines >From a Radical 5-Exo-Trig Cyclization Reaction: Analogs of CC-1065 and the Duocarmycins. Molecules. 2004; 9(3):125-133. https://doi.org/10.3390/90300125

Chicago/Turabian Style

Pati, Hari, Lori Forrest, Heather Townes, Brian Lingerfelt, LuAnne McNulty, and Moses Lee. 2004. "Unexpected Syntheses of seco-Cyclopropyltetrahydroquinolines >From a Radical 5-Exo-Trig Cyclization Reaction: Analogs of CC-1065 and the Duocarmycins" Molecules 9, no. 3: 125-133. https://doi.org/10.3390/90300125

Article Metrics

Back to TopTop